Abstract
Deferasirox is a once-daily oral iron chelator with established dose-dependent efficacy in both adult and pediatric patients with transfusional iron overload. The clinical development program has demonstrated the efficacy of deferasirox for up to 4.5 years of treatment in patients with various underlying anemias, including β-thalassemia, myelodysplastic syndromes, sickle cell disease, aplastic anemia, and other rare anemias. In addition to reducing key indicators of total body iron levels (serum ferritin, liver iron concentration, and toxic labile plasma iron), deferasirox has also demonstrated the ability to remove cardiac iron and prevent future cardiac iron accumulation. Emerging long-term data confirm the tolerability profile of deferasirox, and data on patient compliance render deferasirox a suitable therapeutic option for patients with chronic conditions requiring ongoing iron chelation therapy. Data continue to accumulate in a wide range of patient groups, including those with non-transfusion-dependent anemias such as hereditary hemochromatosis.
| Original language | English |
|---|---|
| Pages (from-to) | 165-173 |
| Number of pages | 9 |
| Journal | Acta Haematologica |
| Volume | 122 |
| Issue number | 2-3 |
| DOIs | |
| Publication status | Published - Nov 2009 |
Fingerprint
Keywords
- Chelation
- Deferasirox
- Myelodysplastic syndromes
- Pediatric anemia
- Sickle cell disease
- Thalassemia
ASJC Scopus subject areas
- Hematology
Cite this
Deferasirox (Exjade®) for the treatment of iron overload. / Cappellini, M. D.; Taher, A.
In: Acta Haematologica, Vol. 122, No. 2-3, 11.2009, p. 165-173.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Deferasirox (Exjade®) for the treatment of iron overload
AU - Cappellini, M. D.
AU - Taher, A.
PY - 2009/11
Y1 - 2009/11
N2 - Deferasirox is a once-daily oral iron chelator with established dose-dependent efficacy in both adult and pediatric patients with transfusional iron overload. The clinical development program has demonstrated the efficacy of deferasirox for up to 4.5 years of treatment in patients with various underlying anemias, including β-thalassemia, myelodysplastic syndromes, sickle cell disease, aplastic anemia, and other rare anemias. In addition to reducing key indicators of total body iron levels (serum ferritin, liver iron concentration, and toxic labile plasma iron), deferasirox has also demonstrated the ability to remove cardiac iron and prevent future cardiac iron accumulation. Emerging long-term data confirm the tolerability profile of deferasirox, and data on patient compliance render deferasirox a suitable therapeutic option for patients with chronic conditions requiring ongoing iron chelation therapy. Data continue to accumulate in a wide range of patient groups, including those with non-transfusion-dependent anemias such as hereditary hemochromatosis.
AB - Deferasirox is a once-daily oral iron chelator with established dose-dependent efficacy in both adult and pediatric patients with transfusional iron overload. The clinical development program has demonstrated the efficacy of deferasirox for up to 4.5 years of treatment in patients with various underlying anemias, including β-thalassemia, myelodysplastic syndromes, sickle cell disease, aplastic anemia, and other rare anemias. In addition to reducing key indicators of total body iron levels (serum ferritin, liver iron concentration, and toxic labile plasma iron), deferasirox has also demonstrated the ability to remove cardiac iron and prevent future cardiac iron accumulation. Emerging long-term data confirm the tolerability profile of deferasirox, and data on patient compliance render deferasirox a suitable therapeutic option for patients with chronic conditions requiring ongoing iron chelation therapy. Data continue to accumulate in a wide range of patient groups, including those with non-transfusion-dependent anemias such as hereditary hemochromatosis.
KW - Chelation
KW - Deferasirox
KW - Myelodysplastic syndromes
KW - Pediatric anemia
KW - Sickle cell disease
KW - Thalassemia
UR - http://www.scopus.com/inward/record.url?scp=70450219836&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70450219836&partnerID=8YFLogxK
U2 - 10.1159/000243801
DO - 10.1159/000243801
M3 - Article
C2 - 19907154
AN - SCOPUS:70450219836
VL - 122
SP - 165
EP - 173
JO - Acta Haematologica
JF - Acta Haematologica
SN - 0001-5792
IS - 2-3
ER -